Clinical Trial Update: Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating benralizumab for reducing oral corticosteroid use in uncontrolled asthma on high-dose ICS-LABA with chronic OCS; results and safety dat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-10-17